ISCT believes Trump's proposed health budget cuts will be disastrous

24 March 2017
trump_big

The International Society of Cellular Therapy (ISCT) believes that the massive and unprecedented budget cuts to US governmental scientific agencies including the (National Institutes of Health (NIH) and National Science Foundation (NSF) proposed by US President Donald Trump, if implemented, will have wide ranging and potentially life threaten in ramifications to science, clinical care and patients in the US and internationally.

ISCT president, Dr Catherine Bollard, states that the ISCT global leadership representing all stakeholders involved in cell therapy around the world believes many of the cuts proposed for the NIH by the Trump administration will directly and dangerously impact the entire international cell therapy, medical and scientific communities.

Dr Bollard highlights the example of the proposed elimination of the Fogarty International Center for Advanced Study in the Health Sciences, the NIH program promoting and funding medical research and training outside the USA. Since the late 1960s, the Center has been instrumental in bringing together the international medical and scientific communities to address global health issues such as HIV/AIDS and Ebola.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical